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TM-2 known as a potential antitumor drug is a novel semi-synthetic taxane derivative. As drug–protein
interactions contribute to insights into pharmacokinetic and pharmacodynamic properties, we eluci-
dated the binding of TM-2 to plasma protein. In this study, a simple, rapid and reliable method was
developed and validated employing equilibrium dialysis for the separation of bound and unbound drugs
and ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) for the
quantitation. Protein binding reached equilibrium within 24 h of incubation at 37 °C. After liquid–liquid
extraction with methyl tert-butyl ether, the samples were separated on Thermo Syncronis UPLC
s
C18
(2.1 mm50 mm, 1.7 mm), and acquisition of mass spectrometric data was performed in multiple re-
action monitoring (MRM) mode via positive electrospray ionization. The assay was linear over the
concentration rang of 5–2000 ng/mL. The intra- and inter-day precisions were 0.1%–14.8%, and the ac-
curacy was from 6.4% to 7.0%. This assay has been successfully applied to a protein binding study of
TM-2 in rat, human and beagle dog plasma. TM-2 showed high protein binding of 81.4%76.5% (rat),
87.9%73.6% (human) and 79.4%74.0% (beagle dog). The results revealed that there was an insigniﬁcant
difference among the three species.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chemotherapy for cancer with the taxanes such as docetaxel
and paclitaxel has played an important role in oncology as cancer
tends to be the number one killer of human beings [1]. The lack of
sufﬁcient antitumor activity of these agents may be a primary and
constitutive deterrent to clinical use. Great attempts have been
made to develop novel derivatives with improved activity and
reduced toxicity. 13-(N-Boc-3-i-butylisoserinoyl-4,10-β-diacetoxy-
2-α-benzoyloxy-5-β-20-epoxy-1,13-α-dihydroxy-9-oxo-19-norcy-
clopropa[g]tax-11-ene (TM-2) (Fig. 1) is a novel semi-synthetic
taxane derivative on the basis of the modiﬁcation of larotaxel.
Compared with docetaxel or larotaxel, TM-2 has been assessed in a
variety of human tumor lines in vitro and shown to display high
anticancer efﬁcacy. Improved cytotoxic activity was noted espe-
cially on cell lines resistant to multi-drug resistance (MDR, KB/
VCR, human cervical adenocarcinoma resistant to vincristine and
MCF-7/ADR, human breast cancer resistant to adriamycin) [2]. Theon and hosting by Elsevier B.V. All
University.in-vivo study on antitumor activity of TM-2 against A549 (human
lung cancer xenografts) in nude mice demonstrated that TM-2
exhibited the tumor control rate value of482.24% and the T/C (the
relative tumor proliferation rate) value of 17.87%. Our previous
study showed that TM-2 is a good candidate for further develop-
ment. The physicochemical properties, degradation kinetics and
the preparation of TM-2 have already been investigated in detail
[3]. The pharmacokinetic studies of TM-2 in both rats and dogs
have also been studied. Also, the major metabolic pathway of TM-
2 in rats was hydroxylation of the taxane ring or the lateral chain
[4–7].
The efﬁcacy and toxicity of the drugs are inﬂuenced by several
factors. Plasma protein binding (PPB), one of the factors, plays an
important role in the pharmacokinetics (PK) and pharmacody-
namics (PD) of a drug and the PPB data are useful for designing
optimal therapeutic dose and estimating safety margins during
drug development. The accurate determination of unbound frac-
tion of drug in plasma is essential in the therapeutic monitoring
because the remaining free fraction closely relates to the phar-
macological effect, and this is especially important for highly
protein-bound drugs. It is evident that taxanes such as paclitaxel,
docetaxel and felotaxel are highly bound to plasma protein [8–10].rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Structures of (A) TM-2 and (B) the IS.
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sible, no data of PPB is available yet. Therefore, the determination
of the PPB of TM-2 becomes one of the important issues for the
complete research and evaluation of the preclinical study.
Various methodologies have been established for determina-
tion of PPB, among which equilibrium dialysis (ED) and ultra-
ﬁltration (UF) are the most frequently employed methods [11–16].
Most methods use equilibrium dialysis instead of ultraﬁltration for
the taxanes such as docetaxel, paclitaxel and cabazitaxel (internal
standard, IS, Fig. 1). The objective of the project was to develop a
relatively simple and reliable method for quantifying TM-2 in rat,
human and beagle dog plasma. Ultra-performance liquid chro-
matography–tandem mass spectrometry (UPLC–MS/MS) is cur-
rently considered the best choice for supporting preclinical studies
due to its selectivity, sensitivity and high output. In light of the
foregoing, equilibrium dialysis and UPLC–MS/MS were employed
in our study and the fully validated method was successfully ap-
plied to a plasma protein binding study of TM-2.2. Experimental
2.1. Chemicals and reagents
TM-2 (purity498.0%) and cabazitaxel (purity498.0%) were
synthesized in the School of Pharmacy, Fudan University (Shang-
hai, China). Acetonitrile and methanol of HPLC-grade were ob-
tained from Fisher Scientiﬁc (Fair Lawn, NJ, USA). HPLC-grade
ammonium acetate was provided by Dikma Co., Ltd. (Beijing,
China). Methyl tert-butyl ether of analytical-grade was purchased
from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).
MD27 equilibrium dialysis membranes with a molecular weight
cut-off of 8000–14,000 Da were purchased from Viskase (Darien,
IL, USA). Blank adult human plasma was collected from healthy
female or male volunteers (Blood Centre of Liaoning, Shenyang,
China). Drug-free rat and beagle dog plasma used in the experi-
ment were collected from different rats and beagle dogs and
stored at 80 °C until use (The Experimental Animal Center of
Shenyang Pharmaceutical University, Shenyang, China). In the
experiment of the method validation, blank plasma from single
source (6 lots of blank matrix) was used for the sample prepara-
tion of selectivity and matric effect. Blank plasma used in the other
parts of the method validation was pooled (rats and beagle dogs)
or mixed-gender (human).
2.2. Instruments and UPLC–MS/MS conditions
The experiment was performed on an ACQUITY™ UPLC system
(Waters Corp., Milford, MA, USA) and a Waters TQD triple quad-
rupole mass spectrometer (Waters Corp., Manchester, UK) equip-
ped with an electrospray ionization source. All data were acquired
in centroid mode by the Masslynx™ NT4.1 software and analyzedby QuanLynx™ program (Waters Corp., Milford, MA, USA). The
analyte was separated on Thermo Syncronis UPLC
s
C18
(2.1 mm50 mm, 1.7 mm) with a thermostated column oven set-
ting at 35 °C. The mobile phase was composed of solvent A
(acetonitrile) and solvent B (2 mM ammonium acetate) at the ﬂow
rate of 0.2 mL/min according to the following linear gradient: 0–
1.5 min, 60%–90% A; 1.5–2.7 min, 90% A; 2.7–2.8 min, 90%–60% A;
2.8–3.5 min, 60% A. The autosampler was conditioned at 8 °C, and
the injection volume was 5 μL.
Mass spectrometric analysis was performed in positive ion
mode under multiple reaction monitoring (MRM) with ion tran-
sitions at m/z 812.39-551.35 and 836.36-555.26 for TM-2 and
the IS, respectively. Spectrometric parameters were as follows:
desolvation temperature of 400 °C, source temperature of 100 °C,
desolvation gas of 550 L/h, cone gas of 40 L/h, dwell time of 0.2 s
and capillary voltage of 3.50 V. The cone voltage were 30 V for TM-
2 and 25 V for the IS, and collision energy was 10 eV for both TM-2
and the IS.
2.3. Preparation of working solutions and standard curves
Individual stock solutions of TM-2 and IS were prepared in
methanol both at 1.0 mg/mL. The stock solution of TM-2 was then
serially diluted with methanol to obtain the working solutions
ranging from 0.05 to 20 mg/mL. The IS working solution of 1 mg/mL
was also prepared with methanol from the primary stock solution.
All the solutions were stored at 4 °C and brought to room tem-
perature before use.
Calibration standards and quality control (QC) samples used to
estimate precision and accuracy of the method were prepared
from two separate sets of solutions in parallel with three different
matrices. Drug-free rat, human and beagle dog plasma was used to
prepare calibration standards and QCs for total TM-2 measure-
ment, and drug-free buffer (phosphate-buffered saline (PBS) buf-
fer, pH 7.4) was used to prepare calibration standards and QCs for
free TM-2 measurement. Calibration standard samples of TM-2 (5,
10, 50, 100, 500, 1000, 2000 ng/mL) were obtained by spiking
10 mL of the appropriate working solutions to 100 mL drug-free
buffer (calibration curve in PBS buffer) or blank rat, human and
beagle dog plasma (calibration curve in plasma). QC samples at
low, middle and high concentrations (10, 100 and 1600 ng/mL)
were prepared separately in the same fashion.
2.4. Sample preparation
A 10 μL aliquot of the IS solution (1000 ng/mL) and 10 μL of
methanol were added to 100 μL of plasma sample (ﬂuid within the
dialysis bags) or the PBS buffer (ﬂuid outside the dialysis bags) in a
5.0 mL plastic centrifuge tube. After vortex-mixing for 1 min, the
mixture was extracted with 2 mL of methyl tert-butyl ether by
shaking for 10 min. The organic and aqueous phases were then
separated by centrifugation at 10,000 rpm (20 °C) for 10 min.
H. Liu et al. / Journal of Pharmaceutical Analysis 6 (2016) 32–3834All supernatants were transferred to a clean plastic tube, and
evaporated to dryness under nitrogen stream at 35 °C. The residue
was reconstituted with 100 μL of acetonitrile : water (3:2, v/v) and
centrifuged again at 13,000 rpm at 4 °C for 5 min, and then 5 μL
aliquot of the resulting solution was injected into the UPLC–MS/
MS system for analysis.
2.5. Quantitative bioanalysis method validation
Validation of the quantitative UPLC–MS/MS method was as-
sessed including speciﬁcity, linearity, precision and accuracy,
recovery, matrix effect and stability according to U.S. Food and
Drug Administration (US-FDA) Guidance for Industry: Bioanaly-
tical Method Validation, European Medicines Agency Guideline on
Bioanalytical Method Validation, and China Food and Drug Ad-
ministration (CFDA) Technical Guideline for Non-clinical Pharma-
cokinetic Study of Chemical Drugs [17–19].
2.5.1. Selectivity
The speciﬁcity of the method was evaluated by analyzing six
blank plasma or PBS buffer samples and spiked plasma or PBS
buffer samples at the lower limit of quantitation (LLOQ). The peak
areas of the endogenous interference co-eluted with the analytes
should be less than 20% of the peak area of the LLOQ standard and
less than 5% of the peak area of the IS.
2.5.2. Linearity
Calibration standards were prepared and analyzed by plotting
the peak area ratios of the analyte to the IS versus the nominal
concentration using a linearly weighed (1/x2) least squares re-
gression method [20] in duplicate on three consecutive days. Ca-
libration curves were considered acceptable when the correlation
coefﬁcient (r) was greater than 0.99 and the bias of the calculated
concentrations was within715% of the nominal concentrations,
except the LLOQ with an allowed deviation of 720%.
2.5.3. LLOQ, precision and accuracy
LLOQ was established by analyzing six blank plasma samples
spiked with 5.0 ng/mL of TM-2 with acceptable precision and ac-
curacy (less than 20% for each criterion). Precision and accuracy
were determined by assessing six replicates of the QC samples at
three levels (10, 100, 1600 ng/mL) on three consecutive validation
days. Intra- and inter-day precisions (RSD, relative standard de-
viation) were required not to exceed 15%, and accuracy (RE, re-
lative error) should be within715%.
2.5.4. Recovery and matric effect (ME)
Recovery values were calculated at three QC levels with six
replicates by comparing the peak areas of the regularly processed
QC samples (A) with those of spiked post-extraction samples (B),
expressed as: A/B100%. Blank plasma from six lots was extracted
and then spiked with the analyte and the IS to evaluate the ME of
the analyte and IS. The peak area in spiked plasma post-extraction
samples (B) was then compared with those of standard solutions
containing the analyte at equivalent concentrations (C), expressed
as: B/C100%.
2.5.5. Stability
The stability of the analyte in rat, human and beagle dog
plasma or PBS buffer was evaluated by analyzing three replicates
of rat, human and beagle dog plasma or PBS buffer samples at
three QC levels under the following conditions: stored at 80 °C
for 1 month, exposed at room temperature for 4 h, undergoing
three freeze–thaw cycles and kept in autosampler tray at 8 °C for
12 h. The samples were considered stable when the assay RE was
within715% of the nominal concentration.2.5.6. Carry-over
Carry-over effect was investigated by injecting blank samples
after calibration standard at the upper limit of quantiﬁcation
(ULOQ). The measured peak area should be less than 20% of the
peak area of the analyte at the LLOQ.
2.6. Equilibrium dialysis
In order to determine the plasma protein binding rates, the
equilibrium dialysis method was used. TM-2 at different designed
concentrations (50, 500, 2000 ng/mL for rat, 50, 200, 1000 ng/mL
for human and 50, 200, 500 ng/mL for beagle dog, the con-
centrations were designed depending on the peak concentration,
distribution phase concentration and elimination phase con-
centration in rats and beagle dog [4,6]) was in-vitro spiked to the
PBS buffer and the blank rat, human or beagle dog plasma was
added into the semi-permeable membrane bag. Prior to analysis,
each of the resulting samples was incubated at 37 °C for 24 h to
achieve equilibrium between plasma and PBS buffer. The ﬂuid
outside and inside the dialysis bags was collected after the in-
cubation. The concentration in the dialysis bag was determined by
UPLC–MS/MS using standard curves as the total concentration, i.e.,
the unbound concentration plus the concentration of drug bound
to protein, and the concentration of the ﬂuid outside the dialysis
bags was measured as the unbound fraction. The percentage of
protein binding was calculated using the following formula: Pro-
tein binding ratio Fu (%)¼(DtDf)/Dt100, where Dt represents
the total drug concentration in the plasma compartment, and
Df is the concentration of the free fractions in the PBS buffer
compartment.
2.7. Data analysis
The results are expressed as mean7standard deviation (SD).
The paired Student's t-test was used for statistical analysis. Dif-
ferences associated with P-values lower than 0.05 were considered
to be statistically signiﬁcant.3. Results and discussion
3.1. Non-speciﬁc binding (NSB) experiment
TM-2 at different designed concentrations (50, 500, 2000 ng/mL)
was spiked to the PBS buffer and 2 mL of drug-free PBS buffer was
added into the semi-permeable membrane bag. After incubation at
37 °C for 24 h, both the ﬂuids inside and outside the dialysis bag
were pretreated according to the sample preparation procedure.
The non-speciﬁc binding of TM-2 to the membrane is expressed as
NSB (%)¼[CnVout–Cd (VoutþVin)]/CnVout100, where Cn is the
nominal concentration of TM-2 spiked to the PBS buffer, Cd is the
concentration of determination, Vout represents the volume of the
PBS buffer spiked with TM-2 outside of the dialysis bag, and Vin
represents the PBS buffer volume added into the dialysis bag. The
mean NSB ratio was less than 10%, suggesting that the non-speciﬁc
binding of TM-2 to the membrane was considered to be negligible.
3.2. Attainment of plasma protein binding steady state
This experiment was conducted to learn when binding of TM-2
reached equilibrium. 20 mL aliquot of PBS buffer spiked with TM-2
at three levels (50, 500, 2000 ng/mL, 50, 200, 1000 ng/mL and 50,
200, 500 ng/mL for rat, human and beagle dog plasma, respec-
tively), and 2 mL of rat, human or beagle dog plasma added into
the dialysis bag were incubated in a brown container for periods of
8, 12, 24 and 48 h. Each timed sample was then prepared and
Fig. 2. Time to attain a steady state of protein binding of TM-2 to rat, human and
beagle dog plasma.
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binding ratios of TM-2 at three concentration levels and different
equilibrium time are illustrated in Fig. 2. As shown in Fig. 2, the
percentage of TM-2 bound progressively increased during the ﬁrst
24 h of incubation, and remained relatively constant throughout
the 24–48 h study period (P40.05). The results demonstrated that
the plasma protein binding reached a steady state or equilibrium
after 24 h incubation. Therefore, a dialysis time of 24 h was used
for all subsequent equilibrium dialysis experiments.
3.3. Method validation
3.3.1. Speciﬁcity
Figs. 3–6 depict the typical chromatograms of blank plasma
(rat, human and beagle dog) sample, PBS buffer and blank plasma
(rat, human and beagle dog) sample spiked with TM-2 at LLOQ
and the IS, and PBS buffer and plasma samples collected afterFig. 3. Typical MRM chromatograms of (A) IS and (B) TM-2 (1: blank rat plasma; 2: blan
(220.7 ng/mL) collected in the dialysis membrane after 24 h equilibrium dialysis of ratequilibrium dialysis. No signiﬁcant endogenous interference co-
eluting with the analyte and the IS was observed in the blank rat,
human and beagle dog plasma and PBS buffer, suggesting that the
validated method was highly selective for the analyte.
3.3.2. Linearity and LLOQ
The calibration curve was linear over the range of 5–
2000 ng/mL in plasma and PBS buffer. The following equations of
the calibration curve were used: in rat plasma: y¼1.36xþ2.02
(r¼0.9940); in human plasma: y¼1.73xþ2.38 (r¼0.9958); in
beagle dog plasma: y ¼1.43xþ5.43 (r¼0.9958); in PBS buffer: y
¼1.82xþ3.05 (r¼0.9941), where y represents the peak area ratio
of each analyte to IS, and x is the nominal concentration of the
analyte. The LLOQs were 5 ng/mL with acceptable precision (RSD)
of 14.8% (rat plasma), 12.5% (human plasma), 18.3% (beagle
dog plasma), 15.0% (PBS buffer) and accuracy (RE) of 4.0% (rat
plasma), 4.0% (human plasma), 6.0% (beagle dog plasma), and
6.0% (PBS buffer).
3.3.3. Precision and accuracy
The accuracy and precision values of TM-2 in rat, human and
beagle dog plasma and PBS buffer at three QC levels (10, 100 and
1600 ng/mL) are shown in Table 1. The intra- and inter-day pre-
cision values for TM-2 in rat, human and beagle dog and PBS buffer
were not more than 14.8%, while the accuracy values were 6.4%
to 7.0% at three QC levels. The results demonstrated that the
method was reliable and reproducible for the determination of
TM-2 in rat, human and beagle dog plasma and PBS buffer.
3.3.4. Recovery and matrix effect
The mean recoveries of the analyte ranged from 69.9% to 101.3%
across the concentration range in rat, human and beagle dog
plasma and PBS buffer (Table 1). In addition, the recoveries of thek rat plasma spiked with TM-2 (5 ng/mL) and IS (100 ng/mL); 3: rat plasma sample
plasma at 50 ng/mL).
Fig. 4. Typical MRM chromatograms of (A) the IS and (B) TM-2 (1: blank human plasma; 2: blank human plasma spiked with TM-2 (5 ng/mL) and the IS (100 ng/mL); 3:
human plasma sample (242.7 ng/mL) collected in the dialysis membrane after 24 h equilibrium dialysis of human plasma at 50 ng/mL).
Fig. 5. Typical MRM chromatograms of (A) the IS and (B) TM-2 (1: blank beagle dog plasma; 2: blank beagle dog plasma spiked with TM-2 (5 ng/mL) and the IS (100 ng/mL);
3: beagle dog plasma sample (125.2 ng/mL) collected out of the dialysis membrane after 24 h equilibrium dialysis of beagle dog plasma at 50 ng/mL).
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Fig. 6. Typical MRM chromatograms of (A) IS and (B) TM-2 (1: blank PBS buffer; 2: blank PBS buffer spiked with TM-2 (5 ng/mL) and IS (100 ng/mL); 3: PBS buffer sample
(25.7 ng/mL) collected out of the dialysis membrane after 24 h equilibrium dialysis of PBS buffer at 50 ng/mL).
Table 1
Precision, accuracy, recovery and matrix effect of TM-2 in rat, human and beagle dog plasma and PBS buffer (n¼6).
Matrices Concentration (ng/mL) Precision (RSD, %) Accuracy (RE, %) Recovery (mean7SD) Matrix effect (mean7SD)
Intra-day Inter-day
Rat plasma 10 11.4 11.9 2.0 69.976.6 90.774.3
100 2.3 8.4 0.5 74.575.7 92.072.6
1600 6.5 7.1 2.6 73.677.6 100.274.7
Human plasma 10 3.3 8.7 6.0 91.2710.8 94.4713.4
100 14.8 7.9 5.3 82.672.9 112.27 4.4
1600 3.5 10.4 6.4 85.678.6 94.071.6
Beagle dog plasma 10 11.8 8.7 4.0 84.378.1 108.878.9
100 8.3 7.2 3.9 90.476.5 93.975.5
1600 7.8 11.7 2.8 101.378.0 110.575.3
PBS buffer 10 14.1 0.1 2.0 75.7711.2 113.5719.2
100 5.7 6.6 7.0 86.777.6 87.478.6
1600 14.5 9.2 0.6 84.275.0 110.077.0
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ranged from 87.4% to 113.5% over the corresponding concentration
ranges in rat, human and beagle dog plasma and PBS buffer (Ta-
ble 1). Moreover, the ME of the IS was between 98.9% and 107.4%.
These data indicated that the ME (ion suppression or enhance-
ment) from the rat, human and beagle dog plasma and PBS buffer
was negligible under the current conditions.
3.3.5. Stability
The results of stability experiments under the mentioned
conditions are presented in Table 2. TM-2 was stable in plasma(rat, human and beagle dog) and PBS buffer after standing at room
temperature for 4 h, in the ready-to-inject samples in autosampler
tray at 8 °C for 12 h, undergoing three freeze–thaw cycles and
stored at 80 °C for 1 month. The stock solutions of both analyte
and the IS stored at 20 °C were stable for 1 month.3.3.6. Carry-over
Carry-over was not found for the analyte and the IS in extracted
double blank plasma (without analyte and the IS) after subsequent
injection of the ULOQ (1600 ng/mL).
Table 2
Stability of TM-2 in rat, human beagle dog plasma and PBS buffer under various storage conditions (n¼3).
Conditions Concentration (ng/mL) Rat plasma Human plasma Beagle dog plasma PBS buffer
RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%)
Three freeze–thaw cycles 10 2.2 15.7 3.7 7.0 10.0 0 19.3 5.3
100 7.1 5.1 6.9 5.5 12.3 5.9 6.0 7.1
1600 3.7 3.3 7.8 1.0 8.7 5.4 4.8 11.3
Room temperature for 4 h 10 13.2 3.3 18.4 6.3 2.6 16.0 12.8 6.3
100 3.7 0.7 2.3 10.8 15.0 1.3 7.5 10.8
1600 9.6 4.8 10.9 1.2 5.0 0.6 14.9 1.2
Frozen at 80 °C for 30 days 10 2.6 12.7 5.8 11.3 3.4 6.0 14.0 7.0
100 5.1 4.6 3.3 12.0 8.8 7.9 10.7 3.0
1600 10.1 1.9 12.3 0.5 2.8 5.2 8.2 2.7
Autosampler at 8 °C for 12 h 10 11.1 7.3 9.6 1.3 11.5 4.0 9.6 6.0
100 4.5 6.3 7.2 3.0 11.9 8.2 4.6 9.1
1600 5.3 5.4 2.7 13.1 4.4 5.8 10.1 2.8
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The present in-vitro study was carried out to determine the
extent of plasma protein binding of TM-2. The bound and unbound
drug from spiked plasma was separated by the equilibrium dialysis
technique. Rat plasma protein binding of TM-2 was 82.2%710.8%,
82.8%73.9% and 79.3%73.9% at 50, 500 and 2000 ng/mL, respec-
tively. Human plasma protein binding of TM-2 was 89.1%70.3%,
85.7%76.3% and 88.9%71.5% at 50, 200 and 1000 ng/mL, respec-
tively. Beagle dog plasma protein binding of TM-2 was 84.2%70.8%,
79.6%73.8% and 78.2%72.3% at 50, 200 and 500 ng/mL, respec-
tively. Concentration dependent rat, human and beagle dog plasma
protein binding was not observed over the selected concentration
range (50–2000 ng/mL for rat plasma, 50–1000 ng/mL for human
plasma and 50–500 ng/mL for beagle dog plasma). All the results
revealed that TM-2 was bound extensively to plasma protein
(Z78.2% bound) and there was no signiﬁcant difference in bound
fractions among these three species (rat, human and beagle bog).4. Conclusion
A rapid, sensitive and simple method based on equilibrium
dialysis and UPLC–MS/MS was developed and validated for the
determination of rat, human and beagle dog plasma protein
binding of TM-2, which could meet the current requirements of
bioanalytical method validation. The results showed that TM-2
had high plasma protein binding in the physiological conditions of
rat, human and beagle dog and there were no obvious differences
among the three species. The method and the results will prove to
be potentially valuable for further study of TM-2.Acknowledgments
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